tetano
Editor, Senior Moderator
J Med Virol
. 2021 Dec 23.
doi: 10.1002/jmv.27547. Online ahead of print.
Repurposing of Mycobacterium indicus pranii for the severe form of COVID -19 patients in India: A cohort study
Naveed Nazir Shah[SUP] 1 [/SUP], Khurshid Ahmad Dar[SUP] 1 [/SUP], Syed Quibtiya[SUP] 2 [/SUP], Aaliya Mohi Ud Din Azad[SUP] 1 [/SUP], Mehvish Mushtaq[SUP] 1 [/SUP], Showkeen Muzamil Bashir[SUP] 3 [/SUP], Muzafar Ahmad Rather[SUP] 3 [/SUP], Sofi Imtiyaz Ali[SUP] 3 [/SUP], Wajid Mohammad Sheikh[SUP] 3 [/SUP], Showkat Ul Nabi[SUP] 4 [/SUP]
Affiliations
Abstract
SARS-CoV-2 induces the production of proinflammatory cytokines, which results in cytokine storm, and immune-modulators like Mycobacterium indicus pranii (MIP) might ameliorate COVID -19 related cytokine storm. Therefore, the present study evaluates whether MIP offers an advantage in the treatment of severe COVID -19 patients infected with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Prospective MIP cohort Study was conducted in chest disease hospitals in Srinagar, Jammu and Kashmir, India. In the present prospective, randomized clinical study, critically severe COVID -19 patients were divided into two groups, the MIP group (n=105) and Best Standard Treatment group (n=210). Procalcitonin, Ferritin, Hs-CRP (High Sensitive C Reactive Protein), D-dimer levels and Interleukin levels on 5[SUP]th[/SUP] -day post-treatment were significantly reduced in the MIP group compared to the BST group. Compared to the BST group, 105 consecutive patients with severe COVID -19 in the MIP group reported early weaning off mechanical ventilation, resolution of chest architecture (CT scan), significant increase in SpO[SUB]2[/SUB] levels and decreased mortality with hazard ratio-0.234 (95% CI-0.264-2.31) (p-value-0.001). MIP restored SpO[SUB]2[/SUB] , immune/inflammatory response, normalized lung abnormalities (Chest CT scan), and reduced mortality without any serious complications. However, there is a need for placebo-controlled double-blind and controlled clinical trials to confirm the efficacy. This article is protected by copyright. All rights reserved.
Keywords: COVID -19; Mechanical ventilation; Mycobacterium indicus pranii; interleukins; proinflammatory response and Oxygen saturation.
. 2021 Dec 23.
doi: 10.1002/jmv.27547. Online ahead of print.
Repurposing of Mycobacterium indicus pranii for the severe form of COVID -19 patients in India: A cohort study
Naveed Nazir Shah[SUP] 1 [/SUP], Khurshid Ahmad Dar[SUP] 1 [/SUP], Syed Quibtiya[SUP] 2 [/SUP], Aaliya Mohi Ud Din Azad[SUP] 1 [/SUP], Mehvish Mushtaq[SUP] 1 [/SUP], Showkeen Muzamil Bashir[SUP] 3 [/SUP], Muzafar Ahmad Rather[SUP] 3 [/SUP], Sofi Imtiyaz Ali[SUP] 3 [/SUP], Wajid Mohammad Sheikh[SUP] 3 [/SUP], Showkat Ul Nabi[SUP] 4 [/SUP]
Affiliations
- PMID: 34951021
- DOI: 10.1002/jmv.27547
Abstract
SARS-CoV-2 induces the production of proinflammatory cytokines, which results in cytokine storm, and immune-modulators like Mycobacterium indicus pranii (MIP) might ameliorate COVID -19 related cytokine storm. Therefore, the present study evaluates whether MIP offers an advantage in the treatment of severe COVID -19 patients infected with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Prospective MIP cohort Study was conducted in chest disease hospitals in Srinagar, Jammu and Kashmir, India. In the present prospective, randomized clinical study, critically severe COVID -19 patients were divided into two groups, the MIP group (n=105) and Best Standard Treatment group (n=210). Procalcitonin, Ferritin, Hs-CRP (High Sensitive C Reactive Protein), D-dimer levels and Interleukin levels on 5[SUP]th[/SUP] -day post-treatment were significantly reduced in the MIP group compared to the BST group. Compared to the BST group, 105 consecutive patients with severe COVID -19 in the MIP group reported early weaning off mechanical ventilation, resolution of chest architecture (CT scan), significant increase in SpO[SUB]2[/SUB] levels and decreased mortality with hazard ratio-0.234 (95% CI-0.264-2.31) (p-value-0.001). MIP restored SpO[SUB]2[/SUB] , immune/inflammatory response, normalized lung abnormalities (Chest CT scan), and reduced mortality without any serious complications. However, there is a need for placebo-controlled double-blind and controlled clinical trials to confirm the efficacy. This article is protected by copyright. All rights reserved.
Keywords: COVID -19; Mechanical ventilation; Mycobacterium indicus pranii; interleukins; proinflammatory response and Oxygen saturation.